Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248526 | PMC |
| http://dx.doi.org/10.4103/0019-5154.143574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Refractory psoriatic arthritis: emerging concepts in whole process management.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Psoriatic arthritis (PsA) is a chronic and progressive inflammatory arthritis associated with psoriasis, mainly affecting the axial and peripheral joints, characterized by a wide range of complex phenotypes, significant heterogeneity, and a multifactorial etiology. To effectively address the distinct challenges in managing PsA, a pivotal emphasis is placed on clarifying the concept of refractory PsA. Here, we propose a distinction between refractory PsA, differentiating between difficult-to-treat PsA (D2T PsA) and Pseudo-D2T PsA.
View Article and Find Full Text PDFAssociation between TLR-2 and TLR-9 gene polymorphisms (rs5743708 and rs5743836) and susceptibility to psoriatic arthritis in Egyptian patients.
Egypt J Immunol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Psoriasis (PsO) is a chronic immune-mediated disease of the skin. Psoriatic arthritis (PsA) is a prevalent chronic inflammatory disease that is associated with joint destruction and disability. The presence of PsO is the single greatest risk factor for the development of PsA.
View Article and Find Full Text PDF"Excluding Myself From What I Need the Most": Experiences of Loneliness in People With Inflammatory Arthritis: A Qualitative Study.
Int J Rheum Dis
January 2025
Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
Objective: Despite advancements in pharmacological treatments, living with inflammatory arthritis (IA) (including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA)) can make it challenging to engage in social activities, which may increase the risk of loneliness. Although loneliness is predominantly prevalent in IA, its origin and impact on mental health status on daily life with IA remain unexplored. Therefore, the objective of this study was to describe the experiences of people with IA in relation to loneliness.
View Article and Find Full Text PDFUnconventional Imaging Methods in Psoriatic Arthritis.
Curr Rheumatol Rep
January 2025
Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Purpose Of Review: Psoriatic arthritis (PsA) is a complex heterogeneous inflammatory disease that affects about one-third of patients with psoriasis. PsA leads to significant physical impairment and reduced quality of life. Therefore, early diagnosis and intervention are critical for improving long-term outcomes.
View Article and Find Full Text PDFIncrease in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study.
Rheumatol Int
January 2025
Department of Rheumatology, AIIMS, New Delhi, India.
Background: Psoriatic arthritis (PsA) significantly contributes to increased morbidity, reduced life expectancy, and higher healthcare costs due to the burden of comorbidities. This study assessed the prevalence of comorbidities in PsA patients in India and explored the influence of age and disease duration on these comorbidities.
Methods: The prospective, multicenter observational study was conducted across seven centers in India, utilizing data from the Indian Rheumatology Association.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!